This article gives an overview of the history of harm reduction in the USA and the political resistance that has accompanied its growth.

This article gives an overview of the history of harm reduction in the USA and the political resistance that has accompanied its growth.
National Harm Reduction Coalition’s Medical Director Dr. Kim Sue joins various guests from programs across the country to highlight the importance of low-barrier access to medications for opioid use.
The California Poison Control System successfully created a hotline to assist frontline health care providers in treating patients with opioid use disorder and highlight the critical role of poison centers in the public health domain.
Calls to the new hotline increased over time, along with CPCS-initiated outreach and advertisement. A majority of questions received by the hotline were related to uncomplicated buprenorphine starts in special populations.
This program engaged and retained a subset of persons experiencing homelessness with OUD in care and on buprenorphine over 12 months. While uninterrupted treatment and abstinence are reasonable outcomes for conventional treatment programs, intermittent treatment with buprenorphine and decreased opioid use were more common in this pilot and may confer important reductions in opioid and injection-related harms.
This case study shares how the Colorado Department of Human Services Behavioral Health Administration (BHA) used federal State Opioid Response grant funds to implement a mobile health model to bring medication-assisted treatment to rural and underserved areas.
This cohort analysis includes clinical service data from the first 15 months of The Spot mobile clinic, from September 4, 2018, to November 23, 2019. The Spot co-located with the Baltimore syringe services program in five locations across the city. Descriptive data are provided for patient demographics and services provided, as well as percent of patients retained in buprenorphine treatment at one and three months. Logistic regression identified factors associated with retention at three months.
In this quality improvement study, comparable to office-based telemedicine programs, 58.51% of patients treated in a mobile telemedicine treatment unit remained in treatment at 90 days. Longer retention was significantly associated with reduced opioid use. These findings suggest that the combination of telemedicine and mobile services is a unique approach to extend access to medications for opioid use disorder to rural areas and is especially relevant in a postpandemic climate; this model demonstrates feasibility and lays the groundwork for adoption in rural populations.
UMass Memorial Medical Center and community partners deployed a mobile addiction service, called the Road to Care. Using this approach, multidisciplinary and interprofessional providers deliver holistic addiction care by centering patients’ needs with respect to scheduling, location, and convenience. This program also extends access to buprenorphine and naloxone among people experiencing homelessness. They demonstrated that a community-based mobile addiction service, anchored within a major medical center, can provide high-volume and high-quality overdose prevention services that facilitate engagement with additional treatment.
The primary goal of this toolkit is to provide clinically relevant information to support high-quality delivery of outpatient OUD care via telehealth, while reducing barriers to starting and maintaining both medication and psychosocial treatments. This toolkit is intended for clinicians, administrators and policymakers who are involved in delivering, managing and considering telehealth for OUD care.



